MASH Matters Webcast

CE / CME

MASH Matters: Multidisciplinary Strategies for Translating the Latest Evidence Into Practice

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: February 11, 2025

Expiration: February 10, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 58-yr-old person with obesity (BMI 34 kg/m2) on a GLP-1 RA for 2 yr and dyslipidemia presents with fatigue and elevated LFTs. A recent liver biopsy confirms steatohepatitis (MASH) with active disease (NAS = 6) and F3 fibrosis. The patient is concerned about the biopsy results and is eager to start treatment. Which of the following medications would be the most appropriate option for this person?

2.

A 67-yr-old person with T2D (controlled by metformin) and severe heart failure (EF = 30%; normal 50% to 70%) presents with elevated LFTs and known steatosis on imaging. The patient is diagnosed with MASH and F3 fibrosis. BMI is 37 kg/m2. Which of the following would you recommend today?

3.

How often do you prescribe GLP-1 RAs to individuals with MASH and obesity?